Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group

Thomas E. Witzig, Susan M. Geyer, Paul J. Kurtin, Joseph P. Colgan, David J. Inwards, Ivana N.M. Micallef, Betsy R. LaPlant, John C. Michalak, Muhammad Salim, Robert J. Dalton, Dennis F. Moore, Craig B. Reeder

Research output: Contribution to journalArticle

44 Scopus citations

Abstract

The aim of this study was to learn the toxicity and efficacy of adding 4 doses of rituximab to a standard platinum-based salvage regimen for relapsed CD20+ B-cell non-Hodgkin lymphoma. Patients were treated with rituximab 375 mg/m2 days 1,8,15, 22 (cycle 1 only); cisplatin 100 mg/m2 over 24 h on day 3, cytosine arabinoside 2 g/m2 IV every 12 h × two doses on day 4, dexamethasone 40 mg PO/IV days 3-6, and G-CSF days 5-14. The ORR was 82% (47/57) with 33% (19/57) complete remissions and 49% (28/57) partial remissions. The duration of response (DR) for the 47 responders was 10.5 months (95% CI: 5.3-16.8). The median time to progression (TTP) was 10.3 months (95% CI: 5.3-14.0), the median event-free survival (EFS) was 5.3 months (95% CI: 3.9-11.0), and the median overall survival was 30.5 months (95% CI: 17.8-60.6). We conclude that rituximab can be safely added to standard DHAP.

Original languageEnglish (US)
Pages (from-to)1074-1080
Number of pages7
JournalLeukemia and Lymphoma
Volume49
Issue number6
DOIs
StatePublished - Jun 2008

Keywords

  • Non-Hodgkin lymphoma
  • Rituximab
  • Salvage chemotherapy
  • Transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group'. Together they form a unique fingerprint.

  • Cite this

    Witzig, T. E., Geyer, S. M., Kurtin, P. J., Colgan, J. P., Inwards, D. J., Micallef, I. N. M., LaPlant, B. R., Michalak, J. C., Salim, M., Dalton, R. J., Moore, D. F., & Reeder, C. B. (2008). Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group. Leukemia and Lymphoma, 49(6), 1074-1080. https://doi.org/10.1080/10428190801993470